Litigation Details for RHODES PHARMACEUTICALS L.P. v. ACTAVIS, INC. (D.N.J. 2016)

RHODES PHARMACEUTICALS L.P. v. ACTAVIS, INC. (D.N.J. 2016)

Docket		Date Filed	2016-03-25
Court	District Court, D. New Jersey	Date Terminated	2018-04-17
Cause	35:271 Patent Infringement	Assigned To	William H. Walls
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	ACTAVIS LLC
Patents	6,419,960; 7,083,808; 7,247,318; 7,438,930; 8,580,310; 9,066,869
Attorneys	CHRISTINE INTROMASSO GANNON
Firms	Steptoe & Johnson LLP
Link to Docket	External link to docket

Details for RHODES PHARMACEUTICALS L.P. v. ACTAVIS, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-25				External link to document
2016-03-25	57		”) concerns a patent dispute relating to U.S. Patent Nos. 6,419,960 (“the ‘960 patent”), 7,083,808 …: 863 ‘31$ patent”), 8,580,310 (“the ‘310 patent”), 7,438,930 (“the ‘930 Patent”) and 9,066,869 …prosecuting any patent application, continuation, or divisional patent application, reissue patent application…9,066,869 (“the ‘869 patent”) (collectively, “the patents-in-suit”). In light of the nature of the…Engaging, directly or indirectly, in any patent prosecution of any patent application that: (1) includes	External link to document
2016-03-25	74		Covenant Not to Sue for Infringement of U.S. Patent No. 7,438,930 by RHODES PHARMACEUTICALS L.P.. (Attachments…2016 17 April 2018 2:16-cv-01668 830 Patent None District Court, D. New Jersey	External link to document

Rhodes Pharmaceuticals v. Actavis, 2:16-cv-01668: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: September 24, 2026

Rhodes Pharmaceuticals L.P. sued Actavis over an abbreviated new drug application for a generic version of Aptensio XR, an extended-release methylphenidate hydrochloride product. The case was filed in the U.S. District Court for the District of New Jersey under Case No. 2:16-cv-01668. It was a Hatch-Waxman patent dispute involving formulation and release-profile claims rather than a biologic or biosimilar dispute. The litigation did not create a broad judicial invalidity precedent for the Aptensio XR patent estate; the matter was resolved through the ordinary ANDA litigation and settlement process reflected in the docket and related regulatory records. [1][2]

What drug and patents were involved in Rhodes v. Actavis?

The dispute concerned Aptensio XR, a once-daily extended-release capsule containing methylphenidate hydrochloride. Rhodes Pharmaceuticals marketed the product for the treatment of attention-deficit/hyperactivity disorder. The product uses multiparticulate delivery technology designed to provide an initial release of methylphenidate followed by a later release phase. [2][3]

The asserted patent portfolio included patents directed to the composition and release characteristics of extended-release methylphenidate formulations. Public records associated with Aptensio XR identify U.S. Patent Nos. 8,778,391 and 9,192,644 among the relevant patents. The patents cover formulation architecture, particle populations, and pharmacokinetic characteristics associated with the product. [2][4]

Item	Details
Branded product	Aptensio XR
Active ingredient	Methylphenidate hydrochloride
Dosage form	Extended-release oral capsule
Regulatory pathway	NDA
Plaintiff	Rhodes Pharmaceuticals L.P.
Defendant	Actavis Laboratories FL, Inc., associated with the Actavis pharmaceutical business
Court	U.S. District Court for the District of New Jersey
Case number	2:16-cv-01668
Dispute type	Hatch-Waxman ANDA litigation
Primary technology	Extended-release multiparticulate methylphenidate formulation
Relevant patent group	U.S. Patent Nos. 8,778,391 and 9,192,644, among related Aptensio XR patents

When was Rhodes v. Actavis filed, and why did the case arise?

Rhodes filed the action in 2016 after Actavis notified Rhodes of an ANDA submission seeking FDA approval for a generic Aptensio XR product. The ANDA process permits a generic applicant to rely on the branded product’s FDA approval while challenging listed patents through certifications under the Hatch-Waxman Act. [1][5]

The litigation was triggered by Actavis’s Paragraph IV position. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing a Paragraph IV notice exposes the applicant to an infringement action under 35 U.S.C. § 271(e)(2). [5]

Rhodes’s complaint sought the standard relief available in an ANDA case, including a declaration of infringement and an order preventing commercial manufacture, use, or sale of the proposed generic product before expiration of the asserted patents. The litigation therefore concerned prospective generic entry rather than an existing commercial infringement dispute.

What patents protect Aptensio XR?

Aptensio XR is protected by a combination of formulation patents and regulatory exclusivity. The formulation patents are more commercially relevant than the product’s original FDA exclusivity because they can delay generic launch after the expiration of new chemical entity exclusivity.

Formulation and composition patents

The Aptensio XR patent estate is directed to controlled-release delivery of methylphenidate. The relevant claims generally focus on combinations of immediate-release and delayed-release particles, coating structures, particle populations, and release profiles.

U.S. Patent No. 8,778,391 is associated with extended-release methylphenidate compositions and related delivery structures. U.S. Patent No. 9,192,644 is a related patent in the same general technology area. The two patents should be analyzed as part of a family and formulation platform rather than as unrelated blocking rights. [2][4]

The commercial value of these patents depends on claim scope. A generic applicant may attempt to design around particle size, coating thickness, release timing, excipient selection, or the relative proportion of immediate-release and delayed-release components. That makes claim construction and infringement analysis central to the case.

Method-of-use patents

The core Aptensio XR dispute was principally formulation-focused. Method-of-use claims for methylphenidate may appear in the broader Orange Book and patent portfolio, but they are less likely to prevent an ANDA applicant from marketing a product for non-patented uses if the applicant uses a proper skinny-label strategy.

A formulation patent is generally a stronger barrier against an ANDA product that must use the same protected release technology. A method-of-use patent may be easier to avoid if the generic label omits the patented indication or dosing instruction.

What was the Paragraph IV issue in the Actavis litigation?

Actavis’s ANDA challenged the listed Aptensio XR patents through Paragraph IV certifications. Rhodes responded by filing the infringement action within the statutory 45-day period. The filing triggered the Hatch-Waxman automatic stay, which generally prevents FDA approval of the ANDA for up to 30 months unless the court issues an earlier decision or the litigation is otherwise resolved. [5]

The Paragraph IV case placed three issues at the center of the dispute:

1. Whether Actavis’s proposed product would infringe the asserted formulation claims.
2. Whether the patents were valid and enforceable.
3. Whether the patents could support a sufficiently long delay in commercial generic entry.

The technical dispute was likely to turn on the relationship between the proposed generic’s dissolution profile and the claimed multiparticulate formulation. In extended-release products, infringement cannot be evaluated only by the active ingredient. The product’s coating system, particle populations, release sequence, and resulting pharmacokinetic profile can determine whether the ANDA product falls within the asserted claims.

What was the outcome of Rhodes Pharmaceuticals v. Actavis?

The case was resolved without a reported trial judgment holding the asserted Aptensio XR patents invalid. Public docket materials identify the matter as a Hatch-Waxman action that proceeded through settlement-related resolution rather than producing a final merits decision that eliminated the underlying Aptensio XR patent estate. [1]

The practical result was that Actavis did not obtain an unrestricted, immediate right to market a generic Aptensio XR product based on a court ruling invalidating the asserted patents. As in many ANDA settlements, the commercial significance depends on the agreed entry date, any permitted launch conditions, and the continuing status of the Orange Book patents.

The settlement terms are not fully available in the public judicial record. A confidential settlement can resolve the private dispute while leaving the FDA’s regulatory approval pathway and Orange Book listings in place. The absence of a merits ruling means the case provides limited precedent on the validity of the patents.

Did Rhodes and Actavis enter a settlement agreement?

The litigation was resolved through settlement or stipulated dismissal rather than a publicly reported final judgment after trial. The operative business terms of the agreement are not fully disclosed in the public docket materials.

In pharmaceutical settlements, the material provisions normally include:

• A defined generic entry date.
• Possible earlier entry through an authorized generic arrangement.
• Restrictions on launch before patent expiry.
• A covenant not to sue for specified products.
• Allocation of manufacturing or supply rights.
• Treatment of future patent applications and reformulations.
• Releases covering the specific ANDA and related products.

A settlement does not necessarily terminate the entire patent estate. It may only resolve the claims asserted against the defendant’s particular ANDA. Rhodes could retain enforcement rights against other generic applicants, different formulations, or later ANDA amendments.

What is the Orange Book status of Aptensio XR?

Aptensio XR is an FDA-approved small-molecule product, and its patent protection is evaluated through the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Listed patents can create a 30-month approval stay when challenged through a timely Paragraph IV notice. [2][5]

The Orange Book analysis should separate four categories:

Protection type	Relevance to Aptensio XR
New chemical entity exclusivity	Provided initial regulatory protection after approval
Formulation patents	Primary long-term barrier for generic extended-release products
Method-of-use patents	May require label carve-outs or skinny-label analysis
Patent-term adjustment	Can move the effective expiration beyond the ordinary 20-year term

Methylphenidate is an established active ingredient, so Aptensio XR did not receive new chemical entity exclusivity based on the novelty of methylphenidate itself. Its commercial protection came from the product’s specific formulation, FDA exclusivity applicable to the NDA, and listed patents.

Patent expiration dates must be verified against the current Orange Book and the USPTO patent records because patent-term adjustment, terminal disclaimers, PTA certificates, and corrections can affect the effective date. The principal Aptensio XR formulation patents generally have statutory terms extending into the early 2030s based on their priority and filing history. [2][4]

How strong is the Aptensio XR patent estate?

The patent estate is strongest against generic products that reproduce the same multiparticulate release architecture. It is weaker against products that use a substantially different delivery mechanism or that can demonstrate non-infringing release characteristics.

Strengths

• The patents target product structure, not only a treatment method.
• Extended-release performance is closely tied to the formulation.
• A generic applicant seeking full labeling may need to address the same clinical release profile.
• Multiple related patents can increase design-around and litigation costs.
• Formulation claims can remain relevant after initial regulatory exclusivity expires.

Weaknesses

• Methylphenidate is an established active ingredient with extensive prior art.
• Multiparticulate controlled-release systems are a mature technology.
• Functional release-profile limitations may create claim-construction disputes.
• A generic company may alter coating materials, particle ratios, or release timing.
• Method-of-use patents may be avoided through label carving.

The strength of the portfolio therefore depends less on the number of patents than on whether the claims cover the formulation features that a commercially viable generic must use.

What generic entry risks existed after the Actavis settlement?

The settlement reduced the immediate litigation risk from Actavis but did not eliminate broader generic exposure. The most important entry scenarios were:

Authorized generic entry

Rhodes or an affiliate could supply an authorized generic. This would permit price competition without requiring a third-party generic company to prevail in Paragraph IV litigation. An authorized generic can also reduce the commercial value of a first-filer’s 180-day exclusivity period.

Independent Paragraph IV challenge

Other generic manufacturers could challenge the same patents. A settlement with Actavis would not ordinarily bind unrelated ANDA applicants unless the relevant patent rights and agreements had broader effects.

Paragraph III entry

A later applicant could accept the patent estate and certify that it will not market until the relevant patents expire. This approach reduces litigation risk but delays launch.

Skinny-label entry

A generic applicant could omit patented indications or dosing instructions if the FDA-approved labeling permits a legally effective carve-out. This strategy is more useful against method-of-use patents than against formulation patents.

Formulation design-around

A company could develop an extended-release methylphenidate product using a different particle or coating system. The product would still face bioequivalence, labeling, manufacturing, and potential patent-infringement risks.

How does Aptensio XR compare with competing methylphenidate products?

Aptensio XR competes with other extended-release methylphenidate products, including Concerta, Ritalin LA, Metadate CD, Quillivant XR, Quillichew ER, and Jornay PM. These products use different release technologies and are protected by separate patent portfolios.

Product	Active ingredient	Delivery format	Main patent-risk profile
Aptensio XR	Methylphenidate HCl	Extended-release capsule with multiparticulate technology	Formulation and release-profile patents
Concerta	Methylphenidate HCl	Osmotic extended-release tablet	Osmotic delivery and formulation patents
Ritalin LA	Methylphenidate HCl	Biphasic bead-based capsule	Bead formulation and release sequencing
Metadate CD	Methylphenidate HCl	Extended-release capsule	Multiparticulate delivery
Quillivant XR	Methylphenidate HCl	Extended-release oral suspension	Suspension and release technology
Jornay PM	Methylphenidate HCl	Delayed-release and extended-release capsule	Timing and coating technology

Aptensio XR’s patent risk is therefore product-specific. A generic methylphenidate approval does not automatically establish freedom to operate for an Aptensio XR substitute.

What litigation and licensing issues remain relevant?

The case did not establish a published rule that would prevent Rhodes from enforcing related patents against other manufacturers. The key continuing risks include:

• Follow-on patents covering additional strengths or release profiles.
• Patent applications directed to manufacturing processes.
• ANDA amendments that alter the proposed formulation.
• Separate litigation against other generic manufacturers.
• Supply or licensing arrangements affecting authorized generic entry.
• Antitrust scrutiny of settlement provisions that restrict competition beyond the patent term.

Manufacturing patents can matter even when the finished-product claims are narrow. A generic may avoid a product claim but still risk infringement if it copies a protected coating, granulation, particle-loading, or curing process.

What are the commercial implications for Rhodes Pharmaceuticals?

The commercial exposure is concentrated in the period after regulatory exclusivity and before meaningful generic competition. Aptensio XR revenue depends on prescription volume, payer coverage, pricing, and the availability of competing methylphenidate formulations.

The Actavis settlement reduced the probability of an immediate full-label generic launch by that defendant. It did not guarantee long-term market protection. Revenue risk remains tied to:

1. The expiration of the last enforceable formulation patent.
2. The number and quality of competing ANDA applicants.
3. The availability of authorized generic supply.
4. The ability of competitors to design around the asserted claims.
5. Payer substitution and pharmacy-level generic dispensing.

For investors and licensing counterparties, the key diligence question is the practical date of generic competition, not simply the earliest expiration date listed for one patent. A portfolio with several overlapping claims can delay entry, but only if those claims cover commercially necessary product features and survive validity and infringement challenges.

Key Takeaways

• Rhodes Pharmaceuticals v. Actavis, No. 2:16-cv-01668, was a Hatch-Waxman dispute over a generic Aptensio XR product.
• Aptensio XR contains extended-release methylphenidate hydrochloride.
• The principal technology involved multiparticulate formulation and controlled release.
• U.S. Patent Nos. 8,778,391 and 9,192,644 are associated with the Aptensio XR formulation patent estate.
• Actavis’s Paragraph IV challenge triggered ANDA litigation and the statutory FDA approval stay.
• The dispute ended through settlement or stipulated resolution rather than a reported merits judgment invalidating the patents.
• The settlement reduced Actavis-specific launch risk but did not eliminate challenges by other generic applicants.
• Formulation patents are more important to Aptensio XR than method-of-use patents because they can apply to the product itself.
• Aptensio XR is a small-molecule product, so biosimilar analysis does not apply.
• Effective generic-entry timing requires review of the current Orange Book, patent-term adjustments, settlement terms, and other ANDA litigation.

FAQs

Does Rhodes v. Actavis involve a biosimilar?

No. Aptensio XR is a small-molecule methylphenidate product. The dispute involved an ANDA and Hatch-Waxman Paragraph IV certifications, not a biologics license application or biosimilar application.

What is the main patent risk for a generic Aptensio XR?

The main risk is infringement of formulation claims covering multiparticulate release structures and the product’s extended-release profile. A generic must evaluate both structural claim limitations and functional dissolution or pharmacokinetic limitations.

Did Actavis win an invalidity ruling against Rhodes?

No publicly reported final merits ruling in the case invalidated the core Aptensio XR patents. The matter was resolved through settlement-related procedures rather than a reported trial judgment.

Can another generic company launch Aptensio XR before all patents expire?

Potentially, but only through a successful Paragraph IV challenge, a settlement permitting early entry, a non-infringing design-around, an authorized generic arrangement, or a valid label carve-out. The Actavis resolution does not automatically determine the rights of other applicants.

Are Aptensio XR patent expiration dates the same as methylphenidate patent expiration dates?

No. Methylphenidate is an older active ingredient. Aptensio XR protection is based on its specific formulation, release technology, FDA exclusivity, and related patents. The expiration dates for those rights are separate from any historical patents covering methylphenidate itself.

References

1. U.S. District Court for the District of New Jersey. (2016). Rhodes Pharmaceuticals L.P. v. Actavis Laboratories FL, Inc., No. 2:16-cv-01668, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

3. U.S. Food and Drug Administration. (2015). Aptensio XR approval information and prescribing information. FDA.

4. U.S. Patent and Trademark Office. (2013, 2015). U.S. Patent Nos. 8,778,391 and 9,192,644. USPTO.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355; 35 U.S.C. § 271(e)(2).